Zynerba Pharmaceuticals, Inc.
ZYNE · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.08 | -0.03 | 0.05 | 0.05 |
| FCF Yield | -51.54% | -38.27% | -23.80% | -30.46% |
| EV / EBITDA | 1.74 | 2.23 | 2.98 | 2.94 |
| Quality | ||||
| ROIC | -38.09% | -25.74% | -17.73% | -16.32% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.78 | 0.78 | 0.71 | 1.11 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -5.73% | -40.00% | 41.63% | -23.72% |
| Safety | ||||
| Net Debt / EBITDA | 3.21 | 4.21 | 5.68 | 6.94 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -33.72 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |